NICE now advises that a topical aminosalicylate should be the first-line approach for inducing remission in all patients with mild-to-moderate ulcerative colitis, with the addition of an oral aminosalicylate in cases of extensive disease or if remission is not achieved after 4 weeks.
If treatment with topical or oral corticosteroids is needed, the new guidance states this should be time-limited (ie, 4 to 8 weeks).
For patients with Crohn's disease, there are new recommendations on maintaining remission after surgery. These apply only to patients with ileocolonic disease who have had complete macroscopic resection within the last 3 months and who have no active residual disease (previously, the recommendations applied to everyone with adverse prognostic factors after surgery).
The updated recommendations for both forms of inflammatory bowel disease are summarised in separate quick-reference MIMS summaries available online.